An analgesic and antipyretic prodrug that is rapidly hydrolyzed to the metabolites 4-methylaminoantipyrine and 4-aminoantipyrine, which both inhibit COX activity (COX-1: IC50s = 2.6 and 20.8 µM, respectively, and COX-2: IC50s = 4.7 and 41.8 µM, respectively); binds to CB1 and CB2 receptors and TRPV1 receptors at low micromolar concentrations when acylated with arachidonic acid.